<DOC>
	<DOCNO>NCT03050151</DOCNO>
	<brief_summary>To collect data actual-use assess technical performance user injection dupilumab auto-injection device patient atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study Dupilumab Auto-injector Device When Used Patients With Atopic Dermatitis</brief_title>
	<detailed_description>Study conduct 2 part ; part A part B . Part A - Patients moderate-to-severe AD randomize receive dupilumab ( dose 1 ) auto-injector ( AI ) device prefilled syringe . Once part A complete , part B randomize patient moderate-to-severe AD receive dupilumab ( dose 2 ) auto-injector ( AI ) device prefilled syringe .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key Male female ≥12 year age Diagnosis chronic atopic dermatitis least 3 year inadequate response topical medication within 6 month screen Willing able comply clinic visit studyrelated procedure Provide sign informed consent Key Patient &lt; 30.0 Kg weight Patient previously participate dupilumab clinical study Patient take treatment An investigational drug within 8 week within 5 halflives ( know ) , whichever longer , baseline visit Immunosuppressive/immunomodulating drug ( e.g. , systemic corticosteroid , cyclosporine , mycophenolatemufti , IFNγ , Janus kinase inhibitor , azathioprine , methotrexate , etc . ) Phototherapy AD within 4 week baseline visit An experimental monoclonal antibody within 5 halflives within 6◦monthsprior visit 1 halflife unknown . Biologic agent within 5 halflives ( know ) 16 week prior baseline visit , whichever longer . Antiimmunoglobulin E therapy ( omalizumab ) within 130 day prior visit 1 . A live ( attenuate ) vaccine within 12 week baseline visit Patient initiate treatment prescription moisturizers moisturizers contain additive ceramide , hyaluronic acid , urea , filaggrin degradation product screen period ( patient may continue use stable dos moisturizers initiate screen visit ) Patient skin comorbidities may interfere study assessment Patient plan anticipated major surgical procedure patient 's participation study . Women childbearing potential unwilling use adequate birth control measure study Pregnant breastfeed woman , woman plan become pregnant breastfeed study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>